

Publications
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
2025
IJTLDopen
Kuksa L, Andrejak C, Haecker B et al
DOI:
in press
A Year in Review on Tuberculosis and Non- tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists
2025
Pathog Immun
Lange C, Bothamley G, Günther G et al
DOI:
10.20411/pai.v10i2.791
Tuberculosis in adult migrants in Europe: a TBnet consensus statement
2025
Eur Respir J
Kunst H, Lange B, Hovardovska O et al
DOI:
10.1183/13993003.01612-2024
Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe
2025
IJTLD Open
Kirakosyan O, Reimann M, Andersen AB et al
DOI:
10.5588/ijtldopen.24.0498
Screening of refugees from Ukraine for TB: a TBnet survey
2024
Int J Tuberc Lung Dis
Argel M, Conde M, Vieira M et al
DOI:
10.5588/ijtld.23.0447
Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe
2024
Clin Microbiol Infect
Günther G, Guglielmetti L, Kherabi Y et al
DOI:
10.1016/j.cmi.2024.03.009
Tuberculosis disease in immunocompromised children and adolescents: a pTBnet multi-centre case-control study
2024
Clin Infect Dis
Rodríguez-Molino P, Tebruegge M, Noguera-Julian A et al
DOI:
10.1093/cid/ciae158
Tuberculosis screening in migrants to the EU/EEA and UK
2023
Eur Respir J
Köhler N, Vasiliu A, Mandalakas AMM et al
DOI:
10.1183/13993003.01230-2023
Tuberculosis in foreign-born persons in Europe
2023
Euro Surveill
Vasiliu A, Köhler N, Altpeter E et al
DOI:
10.2807/1560-7917.ES.2023.28.42.2300051
Performance of QuantiFERON-TB Gold Plus assays in paediatric tuberculosis: a multicentre PTBNET study
2023
Thorax
Buonsenso D, Noguera-Julian A, Moroni R et al
DOI:
10.1136/thorax-2022-218929
Relative cost of multidrug-resistant tuberculosis medicines in Europe.
2023
Int J Tuberc Lung Dis.
Günther G, Guglielmetti L, Leu C, van Leth F, Lange C for the TBnet.
DOI:
10.5588/ijtld.23.0026.
Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.
2023
EClinicalMedicine
Hamada Y, Gupta RK, Quartagno M et al
DOI:
10.1016/j.eclinm.2022.101815
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
2023
Lancet Infect Dis
Domínguez J, Boeree MJ, Cambau E et al.
DOI:
10.1016/S1473-3099(22)00875-1.
Availability and costs of medicines for the treatment of tuberculosis in Europe.
2023
Clin Microbiol Infect
Günther G, Guglielmetti L, Leu C, Lange C, van Leth F for the TBNET*
DOI:
10.1016/j.cmi.2022.07.026.
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
2022
Eur Respir J
Guglielmetti L, Günther G, Leu C et al
DOI:
10.1183/13993003.00388-2022